Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TEVA is probably buying in the open market today. With all the volume here, it's gotta be institutional buying going on.
I think we got in just in time. Holding long and strong on this one. I bet we close at $1.75 today.
Agree! This is a long term hold. I can see that you have been here from the beginning and probably know this stock better than most. I think that we will have a steady climb throughout the next few months. It looks like the institutional buyers are here today by the looks of the bid size.
RNN will ride CLDA's coattails today.
Looks like we have an exciting morning on our hands this Monday morning. It could be the start of something that people will look back on for quite some time. Investors should be able to get in early at below the the $1.69 that TEVA just paid but look back on it in 30 days and we'll see what happens.
Check out RNN. TEVA just bought at a 38% premium and ther was a flurry of after hours trading Friday afternoon.
RNN could have some pretty good legs Monday morning. There was a flurry of AH trading on Friday and two nice articles came out over the weekend. TEVA just bought in on Thursday at a 38% premium.
RNN will run to $2 real quickly. Maybe even by closing on Monday. There was a whole lot of information for investors to study over the weekend and I think the buyers are coming over to see us. This ran to $3.67 this time last year and there has been nothing but positive things happen since then. This could be the next DNDN or HGSI play in my opinion. Kinda think it may get some buyout offers real soon but I hope they wait that out for a while.
I think you got back in just in time. There was a flurry of buying after hours and over 200,000 shares traded bringing it back up to 1.34. Good luck.
Nice article I found on Seeking Alpha this morning.
Rexahn Pharmaceuticals (RNN) is an interesting biopharma with a promising drug pipeline that could generate huge upside reward for investors over the next 12 to 24 months. Investors have the rare opportunity to purchase shares at a discount of over 20% of the price that Teva Pharmaceuticals Industries Limited (TEVA) just paid.
Rexahn is a clinical stage biopharmaceutical company developing and seeking to deliver cures for cancer and disorders of the central nervous system (CNS) to patients worldwide. Rexahn’s pipeline features three drug candidates in Phase II clinical trials and seven or more other drug candidates in pre-clinical development. Rexahn has three clinical stage drug candidates: Archexin, Serdaxin, and Zoraxel. Archexin is an inhibitor of the protein kinase Akt. Archexin is developed for five cancer indications (renal cell carcinoma - RCC, glioblastoma, ovarian cancer, stomach cancer and pancreatic cancer). Its products in the pre-clinical pipeline include RX-1792, RX-5902, RX-3117, RX-8243, RX-0201, RX-0047, RX-21101 and RX-21202.
Rexahn's three drugs in clinical trial are all in Phase IIa clinical trials and I expect that they will be announcing IIb trials shortly (a near-term catalyst). The trials on the following three drugs could be completed by the end of this year:
Archexin
Archexin is in Phase II clinical trials for the treatment of pancreatic cancer with patient enrollment underway. Archexin’s Phase II clinical trial protocol for the treatment of renal cell carcinoma was accepted by the United States Food and Drug Administration. Archexin is a inhibitor of the protein kinase Akt for cancer cell proliferation, survival, angiogenesis, metastasis, and drug resistance.
Serdaxin
The Company is developing Serdaxin for the treatment of depression and neurodegenerative disorders. Rexahn concluded a Phase IIa clinical trial for depressive disorder (MDD) with Serdaxin, and is planning the Phase II clinical trial for Parkinson’s disease (PD)). Serdaxin is a disease modifying drug that protects neurons from damage that can lead to dysfunction and eventual neuronal death. Serdaxin's Phase IIa clinical trial for depression is complete and a Phase IIb trial is under development.
Zoraxel
The Company is developing Zoraxel for treatment of erectile dysfunction (ED). Zoraxel is a developmental-stage drug for sexual dysfunction that directly modulates the sexual activity control center in the brain. Zoraxel improves the action of serotonin and dopamine, brain signaling molecules that play a key role in three phases of male sexual activity: arousal, erection and release. Zoraxel is the ED therapeutic to affect all three of these phases. Preclinical studies demonstrated that Zoraxel improves sexual performance via enhanced motivation and arousal. The Phase IIa clinical trial of Zoraxel is complete.
According to Leonard Bogner, "The global market opportunity is dramatic. The Core Three candidates have a current value of more than $30 billion. And by 2016, these products could provide a revenue stream to Rexahn of well over $100 million, and perhaps $1.25-$1.50/share in profits. Such numbers suggest a stock “target price” of $25-$30." Additionally, Brean Murray Carret & Co. initiated coverage on Rexahn with a Buy rating on December 2, 2010. The firm believes that Rexahn shares are under-appreciated and offer compelling risk/reward.
Key Developments:
•1/20/2011
Rexahn announced that Teva Pharmaceutical purchased 2,334,515 shares of Rexahn's common stock in a private offering for $3.95 million, or $1.692 per share. The investment money will be used for the purpose of supporting the research and development program for the pre-clinical stage, anti-cancer compound RX-3117. After this transaction, Teva will own 6.29% of the outstanding shares of Rexahn. The key here is the effect on cash burn. The Company’s burn rate is growing toward $1-million/month. With this cash flow from Teva, I expect that Rexahn will have adequate funding to initiate its Phase IIb study on Serdaxin with ample cash left over in 2011 to fund all of its ambitious clinical and pre-clinical trials. This forecast does not assume any cash inflow from milestone payments from Teva, nor does it include payments from the US Government Qualifying Therapuetic Discovery Program. I believe that both are probable, but I have erred on the conservative side. And, in fact, the price of Rexahn's stock is more likely to be driven by events rather than financials, but as part of diligence on a biotech company, it is important to ensure adequate funding.
•12/20/2010
Rexahn announced that it was awarded patent 4,546,454 entitled, Antisense Oligonucleotides that Inhibit Expression of HIF-1, by the Japanese Patent Office. Corresponding patents have been issued to Rexahn in other jurisdictions, including the U.S. and Europe. The Japan patent covers Rexahn's preclinical compound RX-0047 and a method of inhibiting the expression of HIF-1 in human cells or tissues. HIF-1, a human protein, is involved in angiogenesis, cancer cell survival, radiation resistance and cancer metastasis. Increased HIF-1 levels are associated with poor prognosis and increased mortality in several tumors. RX-0047 has demonstrated the ability to inhibit the expression of HIF-1 and also to induce toxicity in several cancer cell lines. Preclinical studies to date have demonstrated potent anti-proliferative, anti-tumor and anti-metastatic activities.
•11/22/2010
Rexahn announced that the U.S. Patent & Trademark Office has issued U.S. Patent 7,833,998 entitled, Oral Neurotherapeutic Cephalosporin Sulfoxide and Sulfone-containing Compositions. The patent covers neurotherapeutic pharmaceutical formulation for cefazoline sulfone, cefazoline sulfoxide, ceftriaxone sulfoxide, and ceftriaxone sulfone for treating neurological disease and behavioral and cognitive disorders. It also covers several novel compounds.
•10/19/2010
Rexahn announced the publication of new preclinical data on the development of 3-aryl-1-isoquinolinamines in the European Journal & Medicinal Chemistry [45:5493-5497, 2010]. In the study, various substituted 3-aryl-1-isoquinolinamine derivatives were shown to have cytotoxicity against eight different human cancer cells (breast, prostate, colon, ovary, kidney, pancreas, glioblastoma, melanoma).
•9/7/2010
Rexahn announced that it has submitted a Phase IIb protocol to the U.S. Food and Drug Administration for the clinical study of Serdaxin for the treatment of major depressive disorder (MDD). The Phase IIb study will assess Serdaxin's efficacy as a treatment for major depressive disorder in approximately 300 subjects. The planned double blind, randomized, placebo-controlled trial will be conducted at multiple sites in the U.S. and will measure the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) as the primary efficacy endpoint. I expect that we will hear announcement by Rexahn that the trial will commence in the very near future, which is likely to propel the stock upward.
I was recently contacted by an overseas fund manager in regards to his top stock picks for 2011. Rexahn is on his list as he believes this company has the potential of being north of $5 by the end of 2011 based on the probability that at least 1 of 3 drug's in Rexahn's pipeline will be entering phase 3. That would certainly place Rexahn on the Street's radar and will generate substantial institutional investments, assuming that Teva does not purchase Rexahn outright beforehand.
Rexahn has a market cap of $108M, zero debt, and about $20M cash on hand. The current float is 54M, with Insiders owning 32%. With some of the catalysts mentioned above, Rexahn could easily test its 52-week high of $3.68 set 9 months ago. In my opinion, the stock is considerably undervalued. Given Rexahn's prospects and recent key developments, Rexahn is a compelling buy. Investors buying the stock now should see an easy double from the current share price of $1.30 within the next 6 to 12 months. Watch for new institutional buying and possible new analyst coverage.
Disclosure: I am long RNN.
Seems like a pretty safe price to enter on since Teva likes it so much. I didn't see my ELTP money doing anything for a while so I through it over here.
Just did! Looks very good in the short and long run.
You'll be able to pick up shares for under $2.50 after today's dillution.
It looks like ELTP is in a holding pattern at present. If some good earnings come out, it should get back up to .05 in a flash. I'm waiting on the sidelines to see what happens with the EPIC dispute and the NetPharma suit. I think if these are settled in a positive manner that it could get up to .06 soon. If FDA approval comes in on one or two of the current ANDA's pending it's at .10 overnight.
I went ahead and got out for now. I think Elite has a lot of good things going on but I wanted to watch from the sidelines for a couple weeks to see what happens with the PharmNetwork suit and the EPIC situation. Hopefully they will both go away and earnings will come in good in February. Also, I'm leary of what will happen to the pps if Epic excersises their 40m share warrant at .025. Like to see this get back up to .07 where it belongs and if I see things moving in the right direction, I'll make a move. Good luck guys.
Elite has some very good long term potential. I like to think of them as a meat and potatoes type company. They are not looking to discover some blockbuster drug that has a multi billion dollar market. They have several deals with other companies to co-develop drugs which have markets ranging from 35m to 125m in hopes to get a slice of the pie. They also have their Lodrane product on the market which is being sold by ECR Pharma. ECR Pharma is owned by Hi-Tech Pharma, who recently signed a co-devlopment deal on a drug that currently has a 100m market. Lodrane is currently generating most of Elite's revenue. The company's objective is to generate revenue through maufacturing fees and royalties to fund their future drug developments. They are devloping ELI 154 and ELI 216 which are currently in late stage trials which could potentially bring in some pretty huge income. They hope to find a partner with some deep pockets for these products. There are some issues going on at the present including the dispute with The PharmNetwork, which is also causing issues with their deal with Epic according to their latest 8-K. Other than those two issues, I think there is a lot of upside to Elite both in the short and long terms since their current market cap is only 5m. You should never bet the whole house on just one stock but this one certainly dserves your attention since it has probably found it's bottom.
Looks like someone had to leave the party!
Looks like the mm's are going to let her rise today.
Positive cash flow has been increasing so that shouldn't be a problem. I think there's some positioning going on with that too.
Pre-market trade. Hmmmm. Interesting
Let's take NITE out at the .0455 ask and move on to the next ask of .055 real quick!
We have a couple of ANDA's pending, sales are on the rise, a recent deal with Hi-Tech who owns ERC, the company that markets the Lordane products, over 500,000 in the bank, the Precisiondose deal, the Mikah deal, etc., etc. On top of that Jerry Treppel CEO bought 500,000 shares at .07 recently. Looking for a partner on ELI 154 and Eli 125. Lots of positive indicators that should push the pps up over time. Just one good pr and we are back up to .08 real quick.
The pps isn't what is important for a stock, it's the number of shares that are issued at that price and the total market cap. The revunues as of last quarter were a little over $990,000 and growing, but even if you only averaged 990K over the next three quarters, that would put you at nearly 4m in revenue for a full year on a stock that only has a market cap of 4.4 m. I'll take that as a great pps entry point especially since they are more than likely going to increase their earnings substantially since their Lodrane sales are on the increase and they should launch the sale of Naltrexone this first quarter which could bear fruit this year. They have partnerships with Epic, Pharmnet, and a recently announced deal with Hi-Tech that could all bring in substantial revenues. On top of that, they have ELI-154 & ELI-126 sitting in the wings that could be blockbusters if approved. I wouldn't call this a pump at all but I would call it a very good long term investment that has some real good short term upside. You should consider taking a position on Tuesday, I know I'll be adding more if the pps stays close to what it's at now. Good luck to you .
That would be sweet! I could pay my house off.
Save the good pr for a trading day so it will get noticed more. I'll try to build a position on this one if it doesn't jump too high tomorrow. Good Luck!!!
It was at $1.30 on February 2008 and gradually slid to it's current pps as the economy tanked. During this period of time, there has been no substantial dillution and as of Septmber 2010, there has been nothing but good news come out with all of the partnerships, drug acquisitions, and great earnings news. This seems to be such a good investment to me. I will slowly build my position on ELTP over the next couple of weeks as more funds become available.
It will definately be interesting to see how this palys out this year. Too many good things going for the pps to be where it is. Holding long and strong on this one. I agree that this might be the investment of the year. We should rise to at least .10 leading up to the earnings annoncement and it wouldn't suprise me if we hit .15 to .20 after that.
O.K., Elite's last qaurter's earnings report stated that substantially all of their $994,000 quarterly income came from the manufacturing and sale of Lordane. This is approximately 4m in annual sales just from Lordane. Elite is in a partnership with ECR Pharma on the Lordane product. ECR is owned by Hi-Tech whom Elite recently cut a deal with. Elite has to be worth at least 20M to Hi-Tech just based on the revenue that they generate from ECR. If Hi-Tech bought Elite out, they keep the 4M in Lordan revenue. It doesn't just end there. Elite has other FDA approved drugs that are being prepared to be put on the market that will generate revenue. There are others at the FDA as we speak awaiting approval. Their platform is very unique and may gain in popularity. This puppy should have at least a 25M market cap at this point which is five times that it's at now. I'll bet we hit .25 cents per share within 3 months. HELLOOOOOOOOOOOOOOO!!! This is a retirement investment.
Oops! try again.
Hi-Tech Pharmacal Acquires ECR Pharmaceuticals
AMITYVILLE, N.Y.--(BUSINESS WIRE)--Mar. 2, 2009-- Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) announced today the signing of a definitive agreement under which Hi-Tech acquired the assets of ECR Pharmaceuticals, a privately held branded specialty pharmaceutical company for $5.1 million in an all-cash transaction, which will be paid over an eight month period. Additionally, Hi-Tech may pay up to $4.0 million in performance incentives tied to future ECR product sales and profits. Under the terms of the acquisition Hi-Tech receives rights to ECR’s product line, including branded prescription products for the treatment of allergy, headache and dermatitis/poison ivy. ECR Pharmaceuticals has 45 sales representatives promoting products to physicians and pharmacists in 12 mid-Atlantic and southern states. ECR had net sales of $13.2 million and operating income of $2.0 million in calendar 2008. The company will continue to operate under the name ECR Pharmaceuticals.
“This acquisition allows Hi-Tech to capitalize on ECR’s growing sales, and brings experienced management with a successful track-record developing new products,“ said David Seltzer, President and CEO of Hi-Tech Pharmacal. “The addition of ECR makes Hi-Tech a more diverse and flexible company, as we have an additional outlet to market differentiated products currently in development. We believe that the ECR acquisition will be earnings accretive and cash flow positive in the near term, and contribute to the Company’s long term growth.”
Hi-Tech is a specialty pharmaceutical company developing, manufacturing and marketing generic and branded products. The Company specializes in difficult to manufacture liquid and semi-solid dosage forms and produces a range of sterile ophthalmic, otic and inhalation products. The Company's Health Care Products Division is a leading developer and marketer of branded prescription and OTC products for the diabetes marketplace.
More reading material on EPC if you are bored. This was a 209 8K that I got off Hi-Tech's web site.
Got this off of ECR's web site.
In 2007 the firm received its first NDA for the once daily dosed musculoskeletal relaxant, Amrix® (cyclobenzaprine HCl, extended release). The product's potential in the marketplace exceeded ECR's then capabilities and was divested to Cephalon, Inc. It has become a mainstay in the treatment of low back pain. ECR also developed once daily dosed antihistamine formulations, Lodrane 24 and Lodrane 24D, which its sales force currently markets. Other ECR products are the corticosteroid DexPak TaperPak and the analgesic, Bupap.
In February, 2009 ECR was acquired by Hi-Tech Pharmacal, Amityville, NY, a major supplier of liquid, generic prescription products as well as branded OTC pharmaceuticals. (See Newsline). The combined firms provide enhanced synergy toward the development and marketing of various product opportunities, expands product life cycle potential, and solidifies Hi-Tech's position in both the branded and generic marketplace
Go to www.ecrpharma.com and their home page has Lodrane plastered all over it. ecr is owned by Hi-Tech. Betcha Hi-Tech is looking pretty hard at Elite.
Thanks, that was a great post. Enjoyed reding it again.
I think we will have a slow and steady climb approaching the earnings date of 02/15. .I'm feeling.o8 cents by the earnings release date and .10 if the earnings are impressive. If we get FDA approval on one of their generics, we shoot to .15 real quick.
Love that analogy Scotia. You are absolutely right, this thing does look like it's got a breakot in the making.
Good morning Scotia and good to hear from you again. It will be fun having you on board. I'll get over to the PCFG board for a visit too.
It would be suicide to short ELTP at this time.
Agreed! Just another part of the puzzle that benefits the shareholders.
I think $2 might be a bit optimistic at this point in the game. At the current share structure including the 40M in warrants, that would put the market cap at $276M. There is going to have to be a whole lot of FDA approvals on some blockbuster drugs in order to achieve that kind of money. I do think that .40 or .50 cents is not out of the question though which would put us at a 10 bagger. I'll take that for a short term investment any time. Trellus ought to consider holding for the long term in my opinion. They could hold out for a possible .25 cent pps and really make out like bandits. Their recent selling has not amounted to very much cash and it puts a downward pressure on the pps because investors are skeptical as to why they are selling. Them being the largest holder have a direct intrest in letting the pps rise. It would be in their best intrest to close their eyes and walk away for a while.
Did some snooping and found that HITK owns ECR who partners with ELTP on their Lodrane products. Found this to be very intersting. Their relationship with HITK has been going on for a few years now. It wouldn't suprise me at all if HITK has given some thought to buying ELTP out. The saga continues............